Compare · NET vs SNCE
NET vs SNCE
Side-by-side comparison of Cloudflare Inc. (NET) and Science 37 Holdings Inc. (SNCE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NET and SNCE operate in Computer Software: Prepackaged Software (Technology), so they compete in similar markets.
- NET is the larger of the two at $112.64B, about 122.3x SNCE ($921.1M).
- NET has hit the wire 8 times in the past 4 weeks while SNCE has been quiet.
- NET has more recent analyst coverage (25 ratings vs 5 for SNCE).
- Company
- Cloudflare Inc.
- Science 37 Holdings Inc.
- Price
- $296.11-6.28%
- $5.75+0.17%
- Market cap
- $112.64B
- $921.1M
- 1M return
- -11.40%
- -
- 1Y return
- +41.05%
- -
- Industry
- Computer Software: Prepackaged Software
- Computer Software: Prepackaged Software
- Exchange
- NYSE
- NASDAQ
- IPO
- 2019
- 2020
- News (4w)
- 8
- 0
- Recent ratings
- 25
- 5
Cloudflare Inc.
CloudFlare, Inc. operates a cloud platform that delivers a range of network services to businesses worldwide. The company provides an integrated cloud-based security solution to secure a range of combination of platforms, including public cloud, private cloud, on-premise, software-as-a-service applications, and Internet of Things (IoT) devices. Its security products comprise cloud firewall, bot management, distributed denial of service, IoT, SSL/TLS, secure origin connection, and rate limiting products. The company also offers performance solutions, which include content delivery, intelligent routing, and mobile software development kit, as well as content, mobile, and image optimization solutions. In addition, it provides reliability solutions comprising load balancing, anycast network, virtual backbone, DNS, DNS resolver, and always online solutions that enhances Internet experience and allows customers to run their digital operations efficiently. Further, the company provides Cloudflare internal infrastructure solutions, including on-ramps, which connect users, devices, or locations to Cloudflare's network; and filters, which are the products that protect, inspect, and privilege data. Additionally, it offers developer-based solutions, such as serverless computing/programmable network, website development, domain registration, Cloudflare apps, and analytics; Consumer DNS Resolver, a consumer application to browse the Internet; and Consumer VPN for consumers designed to secure and accelerate traffic on mobile devices. The company serves customers in technology, healthcare, financial services, consumer and retail, and non-profit industries, as well as government. It has a strategic agreement with Baidu, Inc. and JD Cloud & AI. CloudFlare, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.
Latest NET
- Cloudflare Announces Date of Third Quarter 2026 Financial Results
- SEC Form 4 filed by Cloudflare Inc.
- Cloudflare Launches Basin: A More Open and Accessible Data Platform for Developers
- Cloudflare and Deutsche Telekom Join Forces for a Secure and Resilient Internet
- Cloudflare Announces Public Certificate Authority for the Post-Quantum Web
- Director Ledbetter Carl sold $1,765,750 worth of shares (5,000 units at $353.15) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 144 filed by Cloudflare Inc.
- Chief Financial Officer Seifert Thomas J converted options into 10,000 shares and sold $3,324,617 worth of shares (10,000 units at $332.46) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 144 filed by Cloudflare Inc.
- Crusoe Adds Cloudflare CFO Thomas Seifert, Digital Realty Former CEO Bill Stein, and Redwood Materials Founder and CEO JB Straubel to its Board of Directors
Latest SNCE
- Science 37 Completes Third FDA Inspection, Validating Quality of its Direct-to-Patient Site in Pivotal Phase 3 Rare Disease Trial
- Science 37 and Catalent Announce Partnership Enabling Universal Access to Clinical Research
- Science 37 Completes Second FDA Inspection as Enrollment Leader in Phase 3 Asthma Trial
- Science 37 Appoints Tyler Van Horn as CEO to Lead Next Era of Patient-Access Innovation
- Science 37 Nearly Doubles U.S. Enrollment for GSK Phase 3 Rare Disease Trial
- Science 37 Unveils New Corporate Headquarters in Research Triangle Park, NC
- Science 37 Enrolls 42% of Trial Cohort in 8 Weeks
- Science 37 Quickly Impacts Performance in Under-Enrolling Clinical Trials
- Science 37 Surpasses Enrollment Goals, Accelerates Phase 2 Rare Disease Clinical Trial
- Science 37 Metasite™ Undergoes Successful FDA Inspection, Marking Major Milestone in Virtual Site Quality Assurance and Compliance